<DOC>
	<DOCNO>NCT02749825</DOCNO>
	<brief_summary>This research study look Testosterone level patient receive Trelstar versus receive Lupron Zoladex . These drug approve treatment Prostate Cancer FDA .</brief_summary>
	<brief_title>Comparison Trelstar Versus Lupron Zoladex Advanced Prostate Cancer</brief_title>
	<detailed_description>Patients currently receive Lupron Zoladex consent randomized receive either continued treatment drug , randomize Trelstar period 3 month . At end period , testosterone prostate serum antigen ( PSA ) level draw compare previous level determine Trelstar effective previous treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Advanced Prostate Cancer Currently take Lupron Zoladex Stable PSA Baseline testosterone castration level Life expectancy &gt; 6 month Eastern Cooperative Oncology Group performance status 02 Signed , approve informed consent . Known hypersensitivity leuteinizing hormone release hormone ( LHRH ) agonist Ongoing therapy hyperprolactinemic agent Antiandrogen therapy within 28 day prior study start Prior Orchiectomy , hypophysectomy adrenalectomy Chemotherapy , radiotherapy , prostatectomy within 28 day prior study start Use investigational agent 3 month prior enrollment Use systemic corticosteroid within 28 day study Other malignancy within 2 yr prior study start , except curatively treat skin cancer Severe kidney liver failure , base adequate lab value Other medical condition would likely interfere compliance completion study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Trelstar</keyword>
</DOC>